Affordable Access

deepdyve-link
Publisher Website

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

Authors
  • Vélez-Santamaría, Valentina
  • Nedkova, Velina
  • Díez, Laura
  • Homedes, Christian
  • Alberti, M. Antonia
  • Casasnovas, Carlos
Type
Published Article
Journal
Therapeutic Advances in Neurological Disorders
Publisher
SAGE Publications
Publication Date
Jul 01, 2020
Volume
13
Identifiers
DOI: 10.1177/1756286420932035
PMID: 32655688
PMCID: PMC7331764
Source
PubMed Central
Keywords
License
Unknown

Abstract

Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.

Report this publication

Statistics

Seen <100 times